Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX101 Absorption Study in Healthy Volunteers
NCT05319912Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atn-224 in Wilson disease (WD) (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration, Maximum Measured Plasma Concentration and 1 more. Started Apr 2014; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT05319912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319912.